Abundance X Capable, LLC is a newly disclosed Delaware venture capital vehicle with an unusually concentrated initial investor base. Its October 2, 2026 Form D reports $3.75 million already sold to only two investors, a $250,000 minimum investment and an indefinite total offering size. Peter Diamandis is identified as an executive officer and director, while the filing reports no sales commissions, no finder's fees and no paid securities intermediary. The regulatory filing itself is verifiable, but the most important investment question remains unanswered by EDGAR: what exactly does Abundance X Capable own The fund's name creates an obvious potential connection to biotechnology startup Capable, and Capable independently identifies Diamandis among its early backers, but the Form D does not name Capable or disclose any underlying investment. That distinction is central to our assessment.
KEY FINDINGS
Abundance X Capable filed its initial Form D on October 2, 2026 after reporting a September 1 first sale. The issuer classified itself as a venture capital pooled investment fund and claimed Rule 506(b) together with Investment Company Act Sections 3(c) and 3(c)(1). The offering size is indefinite, meaning the $3.75 million reported sold should not be interpreted as a final fund size. There were only two investors at the filing date and no non-accredited investors were reported.
The combination of $3.75 million and two investors is notable. A simple average produces approximately $1.875 million per reported investor, although the actual subscriptions could be very different. The minimum investment disclosed on Form D is $250,000. This is therefore not currently a broadly distributed vehicle composed of dozens of relatively small subscriptions. At least at the initial filing stage, the economics are concentrated among a very small number of investors.
That concentration creates both a verification signal and a risk consideration. It indicates that real capital was reported as sold rather than the issuer merely filing in anticipation of fundraising. But a two-investor fund can also be highly dependent on a very small LP base, and the public filing provides no information about whether the two investors are independent third parties, strategic investors, affiliated persons or entities associated with the same beneficial owner.
PETER DIAMANDIS IS THE MAIN PUBLICLY IDENTIFIABLE PERSON BEHIND THE FILING
The Form D identifies Peter Diamandis as an executive officer and director of Abundance X Capable. That connection substantially improves the fund's public traceability because Diamandis has a long, independently verifiable history in venture investing, technology and startup formation. His public biography describes him as the founder of XPRIZE and an investor focused on exponential technologies, while historical SEC filings connect his name to numerous private companies and investment vehicles.
The relevant point for this review is not his celebrity or reputation. It is regulatory continuity. Diamandis has appeared in previous Form D records involving biotechnology, technology and investment vehicles, making the identity in Abundance X Capable less difficult to verify than the principal behind a newly created anonymous SPV.
A particularly interesting comparison is Abundance Lila II, LLC. That Delaware vehicle filed a Form D in July 2026 reporting $53.15 million sold to 56 investors and also identified Peter Diamandis as an executive officer and director. The Abundance Lila II and Abundance X Capable filings also share the same reported telephone number, while public filing records identify Kenneth Machida as the person signing both filings in a finance capacity.
Those overlaps strongly suggest an operational relationship within a broader Diamandis-associated investment infrastructure. They should not, however, be interpreted as evidence that Abundance Lila II and Abundance X Capable own the same assets, have identical economics or constitute a single fund. They are separate legal issuers with separate CIK numbers and should be evaluated independently.
THE CAPABLE CONNECTION IS PLAUSIBLE BUT SHOULD NOT BE STATED AS A CONFIRMED FUND HOLDING
The most intriguing part of the fund name is the word "Capable." A biotechnology company using exactly that name currently describes itself as building frontier medicines using AI-enabled drug discovery. Capable's own website says it was backed early with $12 million and separately lists Peter Diamandis among its backers.
This creates a credible potential connection between Abundance X Capable and the Capable biotechnology company. However, we found an important evidentiary limit: the Abundance X Capable Form D does not identify Capable as an underlying portfolio company, and the public SEC notice contains no security name, number of shares, SAFE terms, acquisition price or valuation.
For that reason, it would be premature to report that Abundance X Capable definitely exists to purchase Capable securities. The name and Diamandis connection make that interpretation plausible, but confirmation requires the private placement memorandum, operating agreement, subscription materials or another direct transaction document.
This distinction matters for investor research. A fund name can provide a powerful clue about a single-company SPV, but a clue is not the same thing as a disclosed portfolio position. Investors should obtain documentary confirmation of the underlying asset before relying on the apparent name connection.
IF CAPABLE IS THE UNDERLYING ASSET, VALUATION BECOMES A CRITICAL QUESTION
Capable publicly describes itself as an early-stage biotechnology company working at the intersection of artificial intelligence and drug development. Its own recruiting materials have described a $12 million pre-seed financing and referenced a $100 million SAFE cap. The company is pursuing highly ambitious therapeutic programs and has discussed moving toward first-in-human development.
If Abundance X Capable owns an interest in Capable, investors need considerably more information than the startup's headline financing number. They should determine whether the fund acquired a SAFE, preferred equity, common shares, a secondary position or an interest in another SPV. A $100 million SAFE cap, for example, does not mean that every later security or secondary transaction has the same valuation or contractual rights.
SAFE investments can also create dilution and conversion uncertainty. Future financing rounds determine how many shares ultimately result from a SAFE and on what economic terms. Investors need to know the valuation cap, discount, pro-rata rights, most-favored-nation provisions and whether any subsequent financing changed the company's capitalization materially.
Without those terms, the $3.75 million Form D figure tells investors how much the fund reported raising but virtually nothing about whether the underlying asset was purchased at an attractive valuation.
EARLY-STAGE BIOTECH RISK WOULD BE SUBSTANTIAL
If the vehicle is indeed linked to Capable, the underlying risk profile would be materially different from investing in a mature private technology company. Early biotechnology companies face scientific, regulatory, clinical and financing risks before a product can generate meaningful commercial revenue.
A promising preclinical result does not guarantee that a treatment will work safely in humans. Programs can fail because of toxicity, inadequate efficacy, manufacturing issues, regulatory requirements or difficulty reproducing early experimental results. Moving from animal models into human trials is one of the most important risk transitions in biotechnology.
Capable has publicly described ambitious development timelines and an AI-enabled system intended to accelerate drug discovery. Speed can be commercially valuable, but investors should separate development velocity from clinical validation. Drug candidates still face biological uncertainty regardless of how quickly they were designed or screened.
A concentrated SPV exposed to one early-stage biotechnology company would therefore carry substantially greater binary risk than a diversified venture fund holding dozens of unrelated businesses. A successful scientific outcome could create significant upside, while a failed lead program or inability to raise subsequent capital could materially impair the investment.
ONLY TWO INVESTORS CREATES AN UNUSUAL CONCENTRATION PROFILE
The Form D's two-investor count deserves more attention than it might initially receive. At $3.75 million sold, this is a significant amount of capital concentrated across a very small reported investor population.
A concentrated LP base is not inherently negative. Family offices, institutions and sophisticated high-net-worth investors frequently make large commitments to special-purpose vehicles. It can even reduce administrative complexity.
However, investors evaluating the vehicle should understand whether future closings are expected, whether the initial investors have preferential rights and whether side letters create different economics between investors. Form D does not disclose management fee discounts, information rights, liquidity preferences or special governance provisions negotiated by individual LPs.
Because the total offering is indefinite, additional investors may substantially change this picture. The two-investor count is only a snapshot as of the filing date.
THE $250,000 MINIMUM SHOULD NOT BE CONFUSED WITH THE AVERAGE COMMITMENT
The reported outside-investor minimum is $250,000, while the mathematical average amount sold per reported investor is approximately $1.875 million. That gap suggests either one or both initial commitments materially exceeded the minimum, although Form D does not disclose individual subscription amounts.
For prospective investors, the important question is whether $250,000 remains the current standard minimum or whether access depends on negotiated allocations. Special-purpose venture vehicles frequently adjust minimum subscriptions based on available allocation, investor relationship and closing timing.
The private subscription documents, rather than Form D, should determine the actual amount required for participation.
NO SALES COMMISSION OR FINDER'S FEE IS REPORTED
Abundance X Capable reports zero sales commissions and zero finder's fees, and the Form D does not identify a recipient of sales compensation. This differs significantly from vehicles such as EquityZen Series 2386 or ERP Funds IV, where a regulated broker-dealer was explicitly listed as receiving selling compensation.
The absence of a paid placement agent can reduce one layer of visible distribution cost. It also means investors cannot use a broker-dealer relationship as an additional regulatory cross-check for this particular offering based on the Form D.
The filing may indicate that interests were sold directly by the issuer or affiliated persons, but Form D alone does not provide enough information to determine exactly who solicited each investor. Investors should therefore verify who communicated the offering, who received subscription funds and which entity maintains investor records.
NO MATCHED INVESTMENT ADVISER IS IDENTIFIED IN THE PUBLIC FUND RECORD
Our review did not identify a clearly matched investment adviser disclosure for Abundance X Capable through the public fund information reviewed. This should not automatically be treated as a compliance problem. Many private investment structures can operate under different adviser exemptions or organizational arrangements depending on their activities and circumstances.
It does mean that investors should not assume that a well-known individual's involvement is equivalent to having a separately registered investment adviser overseeing the vehicle. The offering documents should state who exercises investment discretion, the manager's legal identity, whether an adviser exemption is being relied upon and who is responsible for valuation and asset custody.
This is particularly important for a concentrated single-company or transaction-specific SPV, where the manager may have relatively narrow discretion after the underlying investment is completed.
RULE 506(B) LIMITS WHAT THE SEC FILING PROVES
Abundance X Capable relies on Rule 506(b) of Regulation D. Rule 506(b) permits private offerings without general solicitation and can include accredited investors together with a limited number of qualifying sophisticated non-accredited investors. The filing reports no non-accredited investors in this offering.
The exemption allows the issuer to raise substantial capital without registering the offering as a public securities offering. That does not mean the SEC examined the investment thesis, verified the underlying asset, approved Peter Diamandis or determined that the $250,000 minimum is appropriate.
Similarly, reliance on Section 3(c)(1) means the vehicle is using an exclusion from Investment Company Act registration. It should not be described as an SEC-registered investment company.
For FilingDossier's purposes, this is an important distinction: the SEC record verifies that a Form D notice exists and reports specific information supplied by the issuer. It does not provide regulatory certification of the fund's underlying economics.
THE INDEFINITE OFFERING SIZE MEANS $3.75 MILLION MAY ONLY BE THE BEGINNING
Abundance X Capable did not report a fixed total offering amount. It selected an indefinite offering size. The current $3.75 million sold therefore represents capital reported through October 2 rather than a final fundraising target.
This matters because future amendments could materially change the investor count and amount sold. A fund that currently appears extremely concentrated could later have a much broader investor base.
It also prevents investors from calculating how much of the intended fund has already been raised. A $3.75 million closing means something very different in a $5 million target vehicle than in a $50 million vehicle. That denominator is currently unavailable from Form D.
RELATED ABUNDANCE VEHICLES ARE USEFUL FOR IDENTITY CHECKS, NOT PERFORMANCE CLAIMS
Abundance Lila II provides evidence that the Abundance naming convention and Diamandis-associated investment activity existed before the October filing. Its July 2026 Form D reported substantially more capital and a much larger investor count.
That regulatory history helps verify continuity, but it does not provide a public track record for Abundance X Capable. Investors should not infer that because another Diamandis-associated vehicle raised tens of millions of dollars, this vehicle will generate similar outcomes.
Form D records show fundraising. They do not report net IRR, realized multiples, write-offs, carried interest, valuations or investor distributions. Any performance claims relating to prior Abundance vehicles should therefore be supported by actual investor reports or independently verifiable financial documentation rather than fundraising totals.
WHAT INVESTORS SHOULD VERIFY BEFORE COMMITTING CAPITAL
The first question should be surprisingly simple: confirm the actual underlying asset. If Abundance X Capable is a Capable biotechnology SPV, the subscription package should explicitly identify the company and the security being acquired. Investors should not rely solely on the fund name.
The next step is to reconstruct the economics. Investors should determine the effective entry valuation, security type, number of shares or SAFE exposure, dilution assumptions, management fees, administrative expenses, carried interest and any sponsor promote. They should also establish whether another intermediary vehicle exists between Abundance X Capable and the underlying operating company.
For a biotechnology investment, additional diligence should cover the scientific program, intellectual-property ownership, regulatory strategy, financing runway, clinical timeline and capital needed to reach meaningful milestones. Investors should distinguish company-generated claims from independently validated results and understand what happens if a future financing round occurs at a lower valuation.
SCAM OR LEGIT ASSESSMENT
The public evidence reviewed supports the existence of Abundance X Capable, LLC as a genuine Form D filer. The SEC record identifies a Delaware entity, $3.75 million sold, two investors, a September 1 first sale and Peter Diamandis as an executive officer and director. Other public records independently establish Diamandis's identity and connect him with prior private-company and investment-vehicle filings.
We did not identify evidence in the reviewed public sources showing that the Abundance X Capable Form D is fabricated or that the issuer is falsely using Diamandis's identity. The separate existence of Abundance Lila II and the overlapping personnel and operational information provide additional continuity.
The largest unresolved issue is not whether the Form D exists. It is what the vehicle actually owns and on what terms. The apparent Capable connection is credible but not confirmed by the Form D itself. That information gap prevents a public researcher from determining whether the $3.75 million was invested at an attractive valuation or whether the security rights appropriately compensate investors for the underlying risk.
WHAT WE THINK
Abundance X Capable is a good example of why private-fund verification must go beyond simply searching EDGAR. The filing is real and the key individual is highly traceable, but the investment economics remain largely private.
The unusual combination of only two investors, a $250,000 minimum and $3.75 million already sold suggests a concentrated sophisticated-investor vehicle. If it is a single-company SPV connected to Capable, investors could be taking concentrated exposure to an early-stage biotechnology company where scientific progress, clinical validation and future financing will matter far more than the existence of the Form D.
Peter Diamandis's involvement is a meaningful identity and network signal, but it should not substitute for valuation analysis. A recognizable sponsor cannot remove dilution, drug-development, financing or liquidity risk.
FINAL
Abundance X Capable, LLC has a verifiable October 2, 2026 Form D reporting $3.75 million sold to two investors, an indefinite offering size, a $250,000 minimum investment and no reported sales commissions or finder's fees. Peter Diamandis is named as an executive officer and director, while a separate Diamandis-associated vehicle, Abundance Lila II, provides additional evidence of continuity around the Abundance investment structure.
The fund name and independent Capable disclosures create a plausible connection to the Capable biotechnology company, which itself lists Diamandis among its backers. However, the Form D does not identify Capable as the underlying asset, so that relationship should not be treated as confirmed until the private offering documents establish it.
Our principal concern is therefore transparency rather than filing authenticity. Investors should verify the underlying asset, entry valuation, security type, dilution exposure, fees, manager structure and liquidity rights before treating the regulatory filing or Diamandis name as evidence of investment quality. Form D verifies an exempt offering notice; it does not tell investors whether the underlying venture investment is fairly priced or likely to succeed.